Introduction

In a significant legal development, Soleno Therapeutics, Inc. (NASDAQ: SLNO) has been hit with a class action lawsuit by the DJS Law Group. The lawsuit alleges that the company violated key provisions of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a), along with Rule 10b-5. This legal action is particularly pertinent for shareholders who acquired shares during the specified class period, which spans from March 26, 2025, to November 4, 2025.

Background of the Case

The allegations against Soleno Therapeutics center around claims of misleading statements and omissions that may have misled investors about the company’s financial health and business operations. The lawsuit points out that during the class period, Soleno Therapeutics made several public statements which, according to the complaint, lacked sufficient backing or were outright false. This has led to significant scrutiny and concerns regarding the accuracy of the company’s disclosures.

Details of the Class Action

Investors who purchased shares of Soleno Therapeutics within the designated dates and suffered financial losses are encouraged to consider joining this class action lawsuit. The DJS Law Group has set a lead plaintiff deadline of May 5, 2026, by which potential lead plaintiffs must file their motions. Importantly, individuals interested in participating in the class action do not need to be appointed as lead plaintiffs to recover losses.

Legal Implications

The Securities Exchange Act of 1934 was established to protect investors from fraud and to ensure transparency in the financial markets. Sections 10(b) and 20(a) specifically address issues related to securities fraud. Section 10(b) prohibits any manipulative or deceptive device in connection with the purchase or sale of any security, while Section 20(a) holds individuals in control positions responsible for the company’s violations.

Rule 10b-5 further elaborates on these violations, making it illegal to make any untrue statement of a material fact or to omit a material fact necessary to make the statements made not misleading. If the allegations against Soleno Therapeutics are proven, the company could face significant penalties and damages, which could also impact its stock price and overall market reputation.

Who Can Join the Class Action?

Eligible participants in the class action include anyone who purchased Soleno Therapeutics shares during the specified class period and suffered losses as a result. This includes both individual investors and institutional investors. Those who believe they qualify are strongly encouraged to reach out to David J. Schwartz at the DJS Law Group to discuss their options for participation. The firm emphasizes that joining the class action is a way for investors to collectively pursue justice and potentially recover their losses.

Next Steps for Investors

• Contact Legal Counsel: Interested investors should reach out to the DJS Law Group for a consultation.
• Document Your Losses: Keep detailed records of your purchases, including dates and amounts, to support your claim.
• Stay Informed: Monitor updates regarding the lawsuit and any developments from Soleno Therapeutics.
• Be Mindful of Deadlines: Pay attention to the lead plaintiff deadline of May 5, 2026, to ensure your eligibility.

The Broader Impact of the Lawsuit

This lawsuit not only poses potential risks for Soleno Therapeutics but also serves as a cautionary tale for investors in the biotech sector. The case highlights the importance of transparency and the responsibilities of publicly traded companies to provide accurate and timely information to their shareholders. As the situation unfolds, it may influence investor confidence and the overall market dynamics within the pharmaceutical and biotechnology industries.

Conclusion

The class action lawsuit against Soleno Therapeutics is a significant development that underscores the need for corporate accountability in the realm of securities law. As investors seek recourse for their financial losses, this case will likely draw attention from both the legal community and the market at large. Investors are urged to stay vigilant and informed as they navigate the complexities of this legal matter.